TMPRSS2 and posterior cortical atrophy: Currently, PTEN/TMPRSS2:ERG is available as a standalone test for men with atypical pathology, high-grade prostatic in situ neoplasia and those with grade group 1 or 2 PCa to provide risk stratification (10).